Objective: To review the pharmacology, pharmacokinetics, and clinical efficacy of ranolazine for the treatment of chronic stable angina.
Data Sources: MEDLINE was searched (1966-February 2006) using the English-language key terms ranolazine and chronic stable angina. Additional studies were identified from the bibliographies of the reviewed literature.
Study Selection And Data Extraction: Studies evaluating ranolazine, alone or in combination with other agents, were incorporated in this review.
Data Synthesis: Ranolazine is a metabolic modulator designed to improve cardiac energy availability and cardiac metabolism. It is believed to be a partial fatty acid oxidation inhibitor. Ranolazine has been shown to improve exercise duration and time to anginal attacks without significantly affecting heart rate or blood pressure. Adverse effects of ranolazine are reported to be dose related. The elimination half-life of ranolazine is estimated to be between 1.4 and 1.9 hours for the immediate-release and 7 hours for sustained-release preparations.
Conclusions: Ranolazine has a unique mechanism of action that is different from that of conventional agents. It has been studied as monotherapy or in combination with other commonly prescribed agents. It appears that ranolazine has a promising safety data profile and does not affect hemodynamic parameters. At this point, although ranolazine should not be used in place of conventional therapy, it appears that ranolazine may be considered in the management of symptomatic patients when standard antianginal medications are not tolerated or are ineffective.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1G367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ranolazine effectively improves clinical symptoms in patients with slow flow coronary arteries: a randomized, double-blind, placebo-controlled clinical trial.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Department of Cardiovascular Diseases, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
The coronary slow flow phenomenon (CSF) causes persistent chest pains that can affect patients' quality of life. We aimed to examine the ranolazine impacts on clinical symptoms in CSF patients. The present randomized, double-blind, placebo-controlled trial consisted of 44 patients with CSF.
View Article and Find Full Text PDFEffect of electrochemical topology on detection sensitivity in MEA assay for drug-induced cardiotoxicity screening.
Biosens Bioelectron
December 2024
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21205, United States; Department of Medicine, Johns Hopkins University, Baltimore, MD, 21205, United States; Institute for NanoBio Technology, Johns Hopkins University, Baltimore, MD, 21218, United States; Center for Microphysiological Systems, Johns Hopkins University, Baltimore, MD, 21205, United States. Electronic address:
Cardiotoxicity remains a major challenge in drug development, accounting for 45% of medication withdrawals due to cardiac ischemia and arrhythmogenicity. To overcome the limitations of traditional multielectrode array (MEA)-based cardiotoxicity assays, we developed a Nafion-coated NanoMEA platform with decoupled reference electrodes, offering enhanced sensitivity for electrophysiological measurements. The 'Decoupled' configuration significantly reduced polarization resistance (Rp) from 12.
View Article and Find Full Text PDFA systematic review of enrolment criteria and treatment efficacy for microvascular angina.
EuroIntervention
January 2025
National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Background: Microvascular angina (MVA) is an important contributor to morbidity and mortality in patients with non-obstructive coronary artery disease. Despite improvements in its recognition and diagnosis, uncertainty remains around the most effective treatment strategy, and more data are needed.
Aims: We aimed to evaluate the quality of patient selection in treatment studies of MVA and provide a contemporary overview of the evidence base for the treatment of MVA.
Unveiling the Longitudinal Journey: 3-Year Follow-up of Women with MINOCA and INOCA in a Specialized Heart Centre.
CJC Open
December 2024
University of British Columbia, Vancouver, British Columbia, Canada.
Background: Myocardial infarction with no obstructive coronary arteries (MINOCA), and ischemia with no obstructive coronary arteries (INOCA), are female-predominant conditions; clinical trials are lacking to guide medical management for the common underlying vasomotor etiologies. Data on long-term outcomes of (M)INOCA patients following attendance at a women's heart centre (WHC) are lacking.
Methods: Women diagnosed with MINOCA (n = 51) or INOCA (n = 112) were prospectively followed for 3 years at the Leslie Diamond WHC (LDWHC) in Vancouver.
Exploring the Effects of Tomatidine ((3β, 5α, 22β, and 25β)-Spirosolan-3-ol) on Voltage-gated Na+ currents: Insights Into Its Ionic Mechanisms of Action on Current Magnitude, Gating, and Frequency Dependence.
J Physiol Investig
November 2024
Department of Physiology, National Cheng Kung University Medical College, Tainan, Taiwan.
Tomatidine, a major tomato glycoalkaloid, is effective for the prevention of skeletal muscle wasting and enhancing mitophagy. However, its effects on transmembrane ionic currents are not well explored. In this study, we explored the interactions between tomatidine and Na+ current.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!